Voyager Therapeutics, Inc. Deferred Revenue Recognized
Voyager Therapeutics, Inc. (VYGR) reported Deferred Revenue Recognized of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-11.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2025-03-11
- Voyager Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2022-03-31 was $653.00K, a 82.02% decline year-over-year.
- Voyager Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2021-03-31 was $3.63M.
- Voyager Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2024 was $0.00.
- Voyager Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Voyager Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2022 was $40.00M, a 26.61% increase from fiscal 2021.
- Voyager Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2021 was $31.59M, a 19.89% increase from fiscal 2020.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month | Contract with Customer, Liability, Revenue Recognized 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-11 | ||||
| 2023-12-31 | $0.00 10-K · filed 2025-03-11 | ||||
| 2022-12-31 | $40.00M 10-K · filed 2025-03-11 | $269.00K 10-K · filed 2023-03-07 | |||
| 2022-09-30 | $2.08M 10-Q · filed 2022-11-08 | ||||
| 2022-06-30 | $1.21M 10-Q · filed 2022-08-04 | ||||
| 2022-03-31 | $653.00K 10-Q · filed 2022-05-04 | ||||
| 2021-12-31 | $31.59M 10-K · filed 2022-03-08 | ||||
| 2021-09-30 | $4.51M 10-Q · filed 2021-11-02 | ||||
| 2021-06-30 | $3.96M 10-Q · filed 2021-08-09 | ||||
| 2021-03-31 | $3.63M 10-Q · filed 2021-05-10 | ||||
| 2020-12-31 | $26.35M 10-K · filed 2021-02-25 | ||||
| 2020-09-30 | $24.37M 10-Q · filed 2020-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |